Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Giulia Orsi

Showing results (21-30 of 60) with videos related to

Pageof 6
Sort By:
Cancer Chemotherapy and Pharmacology|March 12, 2020
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinomaMichele Reni, Umberto Peretti, Silvia Zanon, et al.
Expert Review of Anticancer Therapy|January 6, 2022
The impact of nutritional status on pancreatic cancer therapyGabriele Capurso, Nicolò Pecorelli, Alice Burini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 17, 2023
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapyMarina Macchini, Giulio Belfiori, Stefano Crippa, et al.
Surgery|August 27, 2024
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrenceDomenico Tamburrino, Claudia Arcangeli, Federico De Stefano, et al.
Medical Oncology (Northwood, London, England)|February 2, 2021
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?Andrea Casadei-Gardini, Sara Lonardi, Valeria Smiroldo, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 30, 2023
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinomaGiulia Gasparini, Francesca Aleotti, Marco Palucci, et al.
Cancer Chemotherapy and Pharmacology|November 7, 2020
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patientsMarina Macchini, Umberto Peretti, Giulia Orsi, et al.
Clinical and Translational Radiation Oncology|May 23, 2024
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinomaPaolo Passoni, Michele Reni, Sara Broggi, et al.
Frontiers in Oncology|September 27, 2021
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus <i>nab</i>-paclitaxel for Advanced Pancreatic AdenocarcinomaIlaria Trestini, Luisa Carbognin, Umberto Peretti, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 14, 2024
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variantsCatia Carconi, Carlo Bosi, Mario Scartozzi, et al.
Pageof 6

Showing results (21-30 of 60) with videos related to

Sort By:
Pageof 6
Cancer Chemotherapy and Pharmacology|March 12, 2020
Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinomaMichele Reni, Umberto Peretti, Silvia Zanon, et al.
Expert Review of Anticancer Therapy|January 6, 2022
The impact of nutritional status on pancreatic cancer therapyGabriele Capurso, Nicolò Pecorelli, Alice Burini, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|July 17, 2023
Exploring the optimal therapeutic management of stage ypIA pancreatic ductal adenocarcinoma patients in the era of primary chemotherapyMarina Macchini, Giulio Belfiori, Stefano Crippa, et al.
Surgery|August 27, 2024
Pathologic complete response following neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma: Impact on survival and recurrenceDomenico Tamburrino, Claudia Arcangeli, Federico De Stefano, et al.
Medical Oncology (Northwood, London, England)|February 2, 2021
Extensive molecular reclassification: new perspectives in small bowel adenocarcinoma?Andrea Casadei-Gardini, Sara Lonardi, Valeria Smiroldo, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|April 30, 2023
The role of biliary events in treatment and survival of patients with advanced pancreatic ductal adenocarcinomaGiulia Gasparini, Francesca Aleotti, Marco Palucci, et al.
Cancer Chemotherapy and Pharmacology|November 7, 2020
Exploring chemotherapy holiday and drugs re-challenge in advanced pancreatic cancer patientsMarina Macchini, Umberto Peretti, Giulia Orsi, et al.
Clinical and Translational Radiation Oncology|May 23, 2024
Hypofractionated radiotherapy concomitant to capecitabine after induction chemotherapy for advanced pancreatic adenocarcinomaPaolo Passoni, Michele Reni, Sara Broggi, et al.
Frontiers in Oncology|September 27, 2021
Pancreatic Enzyme Replacement Therapy in Patients Undergoing First-Line Gemcitabine Plus <i>nab</i>-paclitaxel for Advanced Pancreatic AdenocarcinomaIlaria Trestini, Luisa Carbognin, Umberto Peretti, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 14, 2024
A pilot study of chlorambucil in pre-treated metastatic pancreatic adenocarcinoma patients bearing germline BRCA or other DNA damage repair system variantsCatia Carconi, Carlo Bosi, Mario Scartozzi, et al.
Pageof 6